{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-223434","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.852926+00:00","generated_at":"2026-05-17T05:23:07.254724+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027","bullets":["Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.","Expected cash runway extended into at least mid-2027 due to restructuring and milestone payments.","Initial clinical data from STRO-004 (Tissue Factor-targeting exatecan ADC) expected in 2026.","Restructuring costs estimated at $4.1-4.3 million, with majority paid in Q4 2025.","Company plans to initiate clinical studies for at least one additional ADC program beyond STRO-004."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-223434","json":"https://secwatch.observer/filing/0001193125-25-223434.json","markdown":"https://secwatch.observer/filing/0001193125-25-223434.md","text":"https://secwatch.observer/filing/0001193125-25-223434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/0001193125-25-223434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/stro-20250929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:23:07.254724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2a8a4c0528a73c264233586727deebc4c6b4951","claim":"SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $4.1million to $4.3 million (approximately one-third).","evidence_excerpt":"As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/0001193125-25-223434-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.1million to $4.3 million"},{"label":"Headcount","value":"approximately one-third"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}